Home
We are a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
Heart disease is a leading cause of death globally
We are dedicated to discovering novel therapeutic approaches that improve outcomes for patients suffering from underserved heart diseases.
Therapeutic Areas
Our focus is to understand how inflammation and fibrosis contribute to diseases of the heart and to develop therapies, now in clinical trials for rare cardiac conditions, to target these mechanisms and promote healing.
A debilitating syndrome caused by inflammation of the thin fluid-filled sac surrounding the heart (the pericardium) characterized by sharp and stabbing chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
Learn More
A debilitating syndrome caused by inflammation of the thin fluid-filled sac surrounding the heart (the pericardium) and is characterized by sharp and stabbing chest pain, shortness of breath, and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
Learn More
An acute inflammatory disorder of the heart muscle (the myocardium) resulting in chest pain, impaired heart function, and heart rhythm irregularities, and is a leading cause of sudden cardiac death in people under 35 years of age.
Learn MoreAn acute inflammatory disorder of the heart muscle (the myocardium) resulting in chest pain, impaired heart function, and heart rhythm irregularities, and is a leading cause of sudden cardiac death in people under 35 years of age.
Learn More
A chronic, progressive syndrome in which the heart muscle is unable to pump enough blood to meet the body’s needs for blood and oxygen; symptoms include shortness of breath, rapid heart rate, and edema, resulting in reduced exercise capacity, limitations undertaking simple daily activities, and frequent hospitalizations.
Learn MoreDiastolic heart failure, also referred to as heart failure with preserved ejection fraction (HFpEF), occurs when the heart loses its ability to relax normally (because the myocardium has become fibrotic and stiff) and cannot properly fill with blood during the resting period between each beat.
Learn More
Systolic heart failure, also referred to as heart failure with reduced ejection fraction (HFrEF), occurs when the heart loses its ability to contract normally and is unable to pump with sufficient force to push enough blood into circulation.
Learn More
Rachel Freeburg, a resilient woman from Salem, Oregon, shares her story of battling the physical, mental, and financial hurdles of recurrent pericarditis for seven years: “I couldn’t even laugh because I was so exhausted; it rips you apart.”
September 6, 2023Alexa Ritchie, 25, has spent the better part of a decade in a constant battle against a rare and debilitating illness that would change the course of her life forever: “It became routine that every couple of months I was down for 7 to 10 days.”
May 30, 2023Nicole Janes, the mother of 14-year-old Cruze Janes, shares their story of the profound impact of his myocarditis diagnosis: “It started on a Sunday and by Friday he needed to be admitted to the hospital for decreased cardiac function.”
May 9, 2023Five years ago, Newell Rand, aged 23, was diagnosed with chronic myopericarditis after a series of incorrect diagnoses: “The biggest motivation for me is being able to inspire others.”
April 17, 2023Jorge Estevez, 27, lived an active lifestyle as a competitive runner before being diagnosed with viral myocarditis: “My only hope for the future is not just to survive, but to get back to the old me.”
April 9, 2023Krishnamoorthi MK, Youker KA, Bhimaraj A. Annual Scientific Meeting of the Heart Failure Society of America 2022: Basic and Translational Science Posters.
February 23, 2023Lozano O, García-Rivas G, Ramos M, et al. J Am Coll Cardiol. 2020 Mar, 75 (11_Supplement_1) 705.
February 23, 2023Tsao CW, Aday AW, Almarzooq ZI, et al. Circulation. 2023;147(8):e93-e621.
February 21, 2023Martinez-Naya N, Nirar AH, Kim MM et al. American Heart Association Scientific Sessions 2022: Late-Breaking Basic Science Posters (LBP24).
November 5, 2022Key International Research and Clinical Collaborators
We collaborate with world-class researchers and clinicians at international centers of excellence and leverage their expertise in drug development, experimental execution, inflammation and fibrosis, the treatment of cardiovascular diseases, and clinical trial protocol design. Our collaborations provide the optimal advice and knowledge platform as we pursue our purpose: heal the heart with innovative science.
Join our newsletter
Sign up to receive the latest news from Cardiol Therapeutics!
By subscribing you agree to with our Privacy Policy